Thrombectomy Catheter Mantis

Thrombectomy catheter treatment is the process of opening clots with clotting and thawing drug.


In the case of a clot (thrombosis) caused by various reasons in the vein or clot in another vein or in the heart, if the blood flow is gradually occluded (embolism), enough oxygen and nutrients can be prevented from going to the organs fed by this vein. These clots are thawed by the drug and this condition is eliminated which compromises the vitality of the organs.


Angiography is performed before the procedure and the vessel anatomy (structure) is determined and congestion is shown. Insert the catheter into the occluded vein. A clot thawing drug is administered through this catheter. Drug administration lasts an average of 12 hours. As risky conditions such as bleeding may develop during the treatment, the patient is sent to the intensive care unit and followed up. Angiography is performed periodically to determine the degree of clot dissolution and to replace the catheter. The process usually takes 1 day.


A blood test is performed to determine whether the blood and coagulation of the liver and kidneys are normal or not. In the treatment of thrombectomy catheter, the properties and stages of the treatment device applied with Mantis device are as follows;


The battery driven initiates the mechanical rotation of an atraumatic unique cycle shape by aspiration DVT pharmaco-mechanical dextration and controlled and selective infusion of the fluids specified by the physician, including thrombolytic in the peripheral vasculature; double engine volume, low and high speed options and hydrophilic tips are available.


The battery-operated hand-held drive initiates the mechanical rotation of the atraumatic unique loop shape by aspiration.


Protects vessel wall with leaf shaped end design. It also creates a vortex effect to prevent distal embolism and thrombus with TPA. The internal infusion port provides infusion of TPA and contrast media. The tip diameter of the tip diameter can be adjusted from 5 to 20 mm in diameter. It allows the physician to perform treatment depending on the application area and vessel size. Significantly reduces the dose of thrombolytic therapy. It significantly prevents post-thrombolytic syndrome, and most importantly provides a significant advantage for the patient by reducing hospital stay

Leave a Reply